Epclusa (Sofosbuvir/Velpatasvir) Pan-Genotypic HCV Treatment: Mechanism, Efficacy, and Dosing

　　1.Overview and Mechanism

　　Epclusa(sofosbuvir and velpatasvir)is the first pan-genotypic direct-acting antiviral(DAA)combination for chronic hepatitis C virus(HCV)infection,covering all major genotypes(1-6).It simplifies treatment by eliminating the need for genotyping or interferon/ribavirin use in most cases.

　　The regimen works via dual targeting:

　　Sofosbuvir:A nucleotide analog NS5B polymerase inhibitor that terminates viral RNA synthesis.

　　Velpatasvir:An NS5A inhibitor that disrupts viral replication complex assembly and virion release.

　　Achieving sustained virologic response(SVR12 or SVR24)equates to clinical cure.

　　2.Clinical Efficacy and Long-Term Benefits

　　Beyond viral clearance,Epclusa reduces liver inflammation and normalizes transaminase levels.Long-term viral suppression significantly lowers the risk of hepatic decompensation and hepatocellular carcinoma(HCC).

　　3.Comparison with Other DAAs

　　Compared to Zepatier(elbasvir/grazoprevir)and Mavyret(glecaprevir/pibrentasvir):

　　Vs.Zepatier:Epclusa offers broader genotype coverage,particularly superior in genotype 2 and 3 infections.

　　Vs.Mavyret:While Mavyret shows slightly higher SVR in genotype 3 cirrhosis(99%vs~96%),it is not recommended for decompensated cirrhosis.Epclusa remains a preferred option for decompensated patients.

　　4.Treatment Strategies by Liver Function

　　Dosing is primarily guided by Child-Pugh classification:

　　Compensated cirrhosis or no cirrhosis(Child-Pugh A):Epclusa alone for 12 weeks.

　　Decompensated cirrhosis(Child-Pugh B/C):Epclusa plus ribavirin for 12 weeks.Ribavirin dosing is weight-based(e.g.,1000 mg/day if<75 kg,1200 mg/day if≥75 kg,in divided doses).

　　5.Special Populations and Drug Interactions

　　Prior DAA failure:Consider adding ribavirin and extending treatment to 16-24 weeks,especially after NS5A inhibitor failure.

　　Post-liver transplant:Epclusa plus ribavirin is used,with careful immunosuppressant(tacrolimus/cyclosporine)monitoring.

　　Severe renal impairment(eGFR<30):Data are limited;dose adjustment or extended intervals may be considered.

　　Drug interactions:Clinically significant interactions exist with amiodarone and rifampin;thorough medication review is required.